BERLIN (Reuters) – A Roche study into using a combination of tiragolumab and tecentriq to treat a form of lung cancer in a phase III trial did not achieve the desired success, the Swiss pharmaceuticals maker said on Tuesday. The SKYSCRAPER-01 study “did not reach the primary endpoint of overall survival at the final analysis” […]
Health
Roche records setback in phase III study of two lung cancer drugs
Audio By Carbonatix
BERLIN (Reuters) – A Roche study into using a combination of tiragolumab and tecentriq to treat a form of lung cancer in a phase III trial did not achieve the desired success, the Swiss pharmaceuticals maker said on Tuesday.
The SKYSCRAPER-01 study “did not reach the primary endpoint of overall survival at the final analysis” in patients with advanced or metastatic non-small cell lung cancer, it said.
The detailed data will be presented at a medical meeting in 2025, added Roche.
“Roche continuously reviews its study programmes to determine if any adjustments are necessary for the purposes of ongoing research,” it said.
“Roche will apply the same principles to this programme, with additional data from phase III studies across different settings or tumour types anticipated next year.”
(Writing by Miranda Murray; Editing by Christopher Cushing)